Thromb Haemost 1973; 29(02): 490-498
DOI: 10.1055/s-0038-1647788
Original Article
Schattauer GmbH

Enhancement of ADP-induced Platelet Aggregation by Adrenaline in Vivo and Its Prevention

Hiroh Yamazaki
1   Institute for Cardiovascular Diseases, Tokyo Medical and Dental University, School of Medicine, Yushima, Tokyo, Japan
,
Itsuro Kobayashi
1   Institute for Cardiovascular Diseases, Tokyo Medical and Dental University, School of Medicine, Yushima, Tokyo, Japan
,
Tadahiro Sano
1   Institute for Cardiovascular Diseases, Tokyo Medical and Dental University, School of Medicine, Yushima, Tokyo, Japan
,
Takio Shimamoto
1   Institute for Cardiovascular Diseases, Tokyo Medical and Dental University, School of Medicine, Yushima, Tokyo, Japan
› Author Affiliations
Further Information

Publication History

Received for publication 06 June 1972

Publication Date:
24 July 2018 (online)

Summary

The authors previously reported a transient decrease in adhesive platelet count and an enhancement of blood coagulability after administration of a small amount of adrenaline (0.1-1 µg per Kg, i. v.) in man and rabbit. In such circumstances, the sensitivity of platelets to aggregation induced by ADP was studied by an optical density method. Five minutes after i. v. injection of 1 µg per Kg of adrenaline in 10 rabbits, intensity of platelet aggregation increased to 115.1 ± 4.9% (mean ± S. E.) by 10∼5 molar, 121.8 ± 7.8% by 3 × 10-6 molar and 129.4 ± 12.8% of the value before the injection by 10”6 molar ADP. The difference was statistically significant (P<0.01-0.05). The above change was not observed in each group of rabbits injected with saline, 1 µg per Kg of 1-noradrenaline or 0.1 and 10 µg per Kg of adrenaline. Also, it was prevented by oral administration of 10 mg per Kg of phenoxybenzamine or propranolol or aspirin or pyridinolcarbamate 3 hours before the challenge. On the other hand, the enhancement of ADP-induced platelet aggregation was not observed in vitro, when 10-5 or 3 × 10-6 molar and 129.4 ± 12.8% of the value before 10∼6 molar ADP was added to citrated platelet rich plasma (CPRP) of rabbit after incubation at 37°C for 30 second with 0.01, 0.1, 1, 10 or 100 µg per ml of adrenaline or noradrenaline. These results suggest an important interaction between endothelial surface and platelets in connection with the enhancement of ADP-induced platelet aggregation by adrenaline in vivo.

 
  • References

  • 1 Al-Mondhiry H, Marcus A, Al-Mondhiry H, Spaet T. H. 1969; Acétylation of human platelets by aspirin. Federation Proceedings 28: 576.
  • 2 Born G. V. R. 1962; Quantitative investigations into aggregation of blood platelet. Journal of Physiology 162: 67.
  • 3 Born G. V. R, Hume M. 1967; Effects of the numbers and sizes of platelet aggregates on the optical density of plasma. Nature 215: 1027.
  • 4 Bygdeman S, Johnsen Ø. 1969; Studies on the effect of adrenergic blocking drugs on catecholamine-induced platelet aggregation and uptake of noradrenaline and 5-hydroxytrpta- mine. Acta Physiologica Scandinavica 75: 129.
  • 5 Mills D. C. B, Roberts G. C. K. 1967; Effects of adrenaline on human blood platelets. Journal of Physiology 193: 443.
  • 6 Mitchell J. R. A, Sharp A. A. 1964; Platelet clumping in vitro. British Journal of Heamatology 10: 78.
  • 7 O’Brien J. R. 1962; Platelet aggregation Part 2. Some results from a new method of study. Journal of Clinical Pathology 15: 452.
  • 8 O’Brien J. R. 1968; Effects of salicylates on human platelets. Lancet 01: 779.
  • 9 Pinckard R. N, Hawkins D, Farr R. S. 1968; In vitro acétylation of plasma proteins, enzymes and DNA by aspirin. Nature 219: 68.
  • 11 Shimamoto T, Yamazaki H, Inoue M, Fujita T, Sagawa N, Ishioka T, Sunaga T. 1960; Effect of adrenaline and noradrenaline on “siliconelike property” of blood vessels. Proceedings of the Japan Academy 36: 234.
  • 12 Shimamoto T. 1963; The relationship of edematous reaction in arteries to atherosclerosis and thrombosis. Journal of Atherosclerosis Research 03: 87.
  • 13 Shimamoto T, Maezawa H, Yamazaki H, Atsumi T, Fujita T, Ishioka T, Sunaga T. (1966 a): Pyridinolcarbamate, a bradykinin antagonist in veins. American, Heart Journal 71: 297.
  • 14 Shimamoto T, Maezawa H, Yamazaki H, Ishioka T, Sunaga T, Fujita T. (1966 b): Edematous arterial reaction and its relationship to atherosclerosis and thrombosis. In: Bajusz E, Jasmin G. (eds.), Methods and Archievements in Experimental Pathology. Vol. I Karger S. Basel, New York: 337.
  • 15 Sinakos Z, Caen J. P. 1967; Platelet aggregation in mammalians (human, rat, rabbit, guinea-pig, horse, dog) ; a comparative study. Thrombosis et Diathesis Haemorrhagica 17: 99.
  • 16 Yamazaki H, Sano T, Odakura T, Takeuchi K, Shimamoto T. (1970 a): Electrocardiographic and hematological changes by exercise test in coronary patients and pyridinol- carbamate pretreatment. A double-blind crossover trial. American Heart Journal. 79 640.
  • 17 Yamazaki H, Kobayashi I, Shimamoto T. (1970 b): Enhancement of ADP-induced platelet aggregation by exercise test in coronary patients and its prevention by pyridinolcarba- mate. Thrombosis et Diathesis Haemorrhagica 24: 438.
  • 18 Yamazaki H, Sano T, Odakura T, Takeuchi K, Matsumura T, Hosaki S, Shimamoto T. 1971; Appearance of thrombogenic tendency induced by adrenaline and its prevention by ß-adrenergic blocking agent, nialamide and pyridinolcarbamate. Thrombosis et Diathesis Haemorrhagica 26: 251.
  • 19 Zucker M. B. 1961. Contribution to Discussion. In Johnson S. A, Monto R. W, Rebuck J. W, Horn R. C. (ed.), Blood Platelets . Little Brown and Co; Boston: 141.